Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

Basil S. Lewis, Shamir R. Mehta, Keith A A Fox, David A. Halon, Feng Zhao, Ron J G Peters, M. Keltai, Andrzej Budaj, Salim Yusuf

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: The CURE study demonstrated the benefit of clopidogrel in patients with non-ST elevation (NSTE) acute coronary syndromes (ACSs), including those undergoing percutaneous coronary intervention (PCI). It did not report the relation between clopidogrel and timing of PCI or, more specifically, the role of clopidogrel in patients managed with an early interventional strategy, the current preferred treatment option for patients with NSTE ACSs. In the present study, we examined the relation between clopidogrel therapy, timing of PCI, and cardiovascular (CV) events in patients participating in the CURE study. Methods: A total of 12 562 patients with NSTE ACSs was randomized in double-blind fashion to clopidogrel or placebo (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year. We analyzed the data of the 2658 CURE patients undergoing PCI and related the incidence of outcome events (CV death/myocardial infarction [MI]) to timing of PCI after randomization: early (

Original languageEnglish
Pages (from-to)1177-1184
Number of pages8
JournalAmerican Heart Journal
Volume150
Issue number6
DOIs
Publication statusPublished - Dec 2005

Fingerprint

clopidogrel
Unstable Angina
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Random Allocation
Aspirin
Myocardial Infarction
Placebos

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes : Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. / Lewis, Basil S.; Mehta, Shamir R.; Fox, Keith A A; Halon, David A.; Zhao, Feng; Peters, Ron J G; Keltai, M.; Budaj, Andrzej; Yusuf, Salim.

In: American Heart Journal, Vol. 150, No. 6, 12.2005, p. 1177-1184.

Research output: Contribution to journalArticle

Lewis, Basil S. ; Mehta, Shamir R. ; Fox, Keith A A ; Halon, David A. ; Zhao, Feng ; Peters, Ron J G ; Keltai, M. ; Budaj, Andrzej ; Yusuf, Salim. / Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes : Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. In: American Heart Journal. 2005 ; Vol. 150, No. 6. pp. 1177-1184.
@article{6fd83a3a553e42f9b9a29b157b379692,
title = "Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study",
abstract = "Background: The CURE study demonstrated the benefit of clopidogrel in patients with non-ST elevation (NSTE) acute coronary syndromes (ACSs), including those undergoing percutaneous coronary intervention (PCI). It did not report the relation between clopidogrel and timing of PCI or, more specifically, the role of clopidogrel in patients managed with an early interventional strategy, the current preferred treatment option for patients with NSTE ACSs. In the present study, we examined the relation between clopidogrel therapy, timing of PCI, and cardiovascular (CV) events in patients participating in the CURE study. Methods: A total of 12 562 patients with NSTE ACSs was randomized in double-blind fashion to clopidogrel or placebo (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year. We analyzed the data of the 2658 CURE patients undergoing PCI and related the incidence of outcome events (CV death/myocardial infarction [MI]) to timing of PCI after randomization: early (",
author = "Lewis, {Basil S.} and Mehta, {Shamir R.} and Fox, {Keith A A} and Halon, {David A.} and Feng Zhao and Peters, {Ron J G} and M. Keltai and Andrzej Budaj and Salim Yusuf",
year = "2005",
month = "12",
doi = "10.1016/j.ahj.2005.01.044",
language = "English",
volume = "150",
pages = "1177--1184",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes

T2 - Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

AU - Lewis, Basil S.

AU - Mehta, Shamir R.

AU - Fox, Keith A A

AU - Halon, David A.

AU - Zhao, Feng

AU - Peters, Ron J G

AU - Keltai, M.

AU - Budaj, Andrzej

AU - Yusuf, Salim

PY - 2005/12

Y1 - 2005/12

N2 - Background: The CURE study demonstrated the benefit of clopidogrel in patients with non-ST elevation (NSTE) acute coronary syndromes (ACSs), including those undergoing percutaneous coronary intervention (PCI). It did not report the relation between clopidogrel and timing of PCI or, more specifically, the role of clopidogrel in patients managed with an early interventional strategy, the current preferred treatment option for patients with NSTE ACSs. In the present study, we examined the relation between clopidogrel therapy, timing of PCI, and cardiovascular (CV) events in patients participating in the CURE study. Methods: A total of 12 562 patients with NSTE ACSs was randomized in double-blind fashion to clopidogrel or placebo (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year. We analyzed the data of the 2658 CURE patients undergoing PCI and related the incidence of outcome events (CV death/myocardial infarction [MI]) to timing of PCI after randomization: early (

AB - Background: The CURE study demonstrated the benefit of clopidogrel in patients with non-ST elevation (NSTE) acute coronary syndromes (ACSs), including those undergoing percutaneous coronary intervention (PCI). It did not report the relation between clopidogrel and timing of PCI or, more specifically, the role of clopidogrel in patients managed with an early interventional strategy, the current preferred treatment option for patients with NSTE ACSs. In the present study, we examined the relation between clopidogrel therapy, timing of PCI, and cardiovascular (CV) events in patients participating in the CURE study. Methods: A total of 12 562 patients with NSTE ACSs was randomized in double-blind fashion to clopidogrel or placebo (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year. We analyzed the data of the 2658 CURE patients undergoing PCI and related the incidence of outcome events (CV death/myocardial infarction [MI]) to timing of PCI after randomization: early (

UR - http://www.scopus.com/inward/record.url?scp=28844451590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844451590&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2005.01.044

DO - 10.1016/j.ahj.2005.01.044

M3 - Article

C2 - 16338255

AN - SCOPUS:28844451590

VL - 150

SP - 1177

EP - 1184

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -